AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$DCTH

Delcath (DCTH) Q3 2026 Earnings Call Transcript

Delcath (DCTH) reported Q3 2026 revenue of $35.1M, up 71% YoY, driven by HEPZATO KIT adoption. The company added new treatment centers, including AdventHealth, and expects 36 centers by year-end. Clinical trials are progressing, with a Phase II colorectal trial on track for interim analysis in mid-2027. Full-year revenue guidance was raised to $115M-$117M, with Q4 expected to grow 25%-34% YoY.

Original reporting
finance.yahoo.com
Published Nov 9, 2026, 6:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 6:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Delcath (DCTH) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$DCTHBullishMed
01

Why it matters

Earnings beat and raised guidance suggest accelerating commercial adoption and operational leverage.

02

Market read

Micro‑cap biotech earnings with guidance raise; relevant for sector‑focused traders.

03

What to watch

Potential regulatory delays for upcoming INDs and cash burn from continued network build‑out could pressure the stock.

Relevance 7/10Novelty 8/10Timing: post‑earnings release today

Background

Delcath Systems provides hepatic perfusion therapy (HEPZATO KIT, CHEMOSAT) for liver‑dominant cancers.

Company-level read

Ticker impact

$DCTHBullishHigh confidence
Context

Q3 2026 earnings call disclosed record $35.1M revenue, raised full-year guidance to $115‑$117M and highlighted network expansion.

Expected impact

likely upward pressure as investors price in stronger revenue and guidance

Evidence & confidence

First report of earnings and guidance for a micro‑cap biotech; numbers exceed prior expectations and indicate growth trajectory.

Market effects

Sector

Strengthens outlook for hepatic drug delivery and regional chemotherapy sector.

Regional

May boost investor sentiment toward U.S. biotech firms with niche delivery platforms.

Global

Limited to biotech investors; no broad market impact.

Counterpoint

What could challenge this read

Guidance may be optimistic given slower enrollment in breast cancer trial and reliance on network expansion.

Key entities

  • company
    Delcath Systems Inc.

    Developer of hepatic drug delivery platforms.

  • partner
    University of Nebraska

    New treatment center added to the network.

  • partner
    AdventHealth

    Large integrated health system joining the network.

Read at source← All news

StoryDelcath Systems posts Q3 2026 results, lifts full‑year revenue guidance

Also covered by

4 outlets

Related articles

$DCTHHighAI 8/10

Delcath Systems Inc (DCTH) (Q3 2026) Earnings Call Highlights: Record Revenue, Raised

Delcath Systems (DCTH) reported Q3 2026 revenue of $35.1M, up 71% YoY, driven by HEPZATO KIT sales. CEO Gerard Michel cited therapy adoption, physician demand, and expanded capacity as growth drivers. The company raised full-year revenue guidance to $115M-$117M. Q4 guidance implies a step-down due to holiday impact, with new patient starts expected to slow. The Phase II colorectal cancer trial interim analysis is now expected in Q2 or Q3 2027.

finance.yahoo.com
$EDSAMedAI 8/10

Healthcare Stocks Rally: EDSA And DCTH Jump 30%, VIR And IMVT Also Gain

Edesa Biotech (EDSA) and Delcath Systems (DCTH) shares rose 30% after signing a licensing deal and reporting strong Q3 results, respectively. Immunovant (IMVT) and Vir Biotechnology (VIR) shares gained 13% and 14% following positive clinical trial data. EDSA received $12M upfront, DCTH raised FY26 revenue outlook, IMVT met primary endpoint, and VIR showed undetectable HDV RNA in 28 patients.

rttnews.com
$DCTHMed

Delcath Systems Reports 70% Revenue Growth in Q3 2026 and Raises Full-Year Guidance to $115 Million–$117 Million

Delcath Systems (DCTH) reported Q3 2026 revenue of $35.1M, up 70% YoY, driven by higher sales of its liver cancer treatment products. The company raised its full-year revenue guidance to $115M–$117M. Net income increased to $7.0M, and gross margin improved to 89%. HEPZATO KIT revenue grew 69% to $32.7M, while European CHEMOSAT revenue rose to $2.4M. Adjusted EBITDA increased to $11.5M, and operating cash flow reached $8.2M. Delcath also advanced its clinical development programs.

finance.yahoo.com
$DCTHMed

Delcath Systems Q3 Earnings Call Highlights

Delcath Systems (DCTH) raised its 2026 revenue guidance to $115M-$117M, projecting HEPZATO KIT volume growth of at least 41% over 2025. Q4 revenue is expected to be $25.8M-$27.8M, down sequentially but up 25%-34% year-over-year, due to holiday scheduling. Growth is attributed to increased use of HEPZATO, patient awareness, and expanded capacity at centers like MD Anderson and Mass General.

finance.yahoo.com